Brief: Sandoz Announces Strategic Collaboration With Henlius On Up To 10 Biosimilars
BRIEF-Sandoz Announces Strategic Collaboration With Henlius On Up To 10 Biosimilars Aug 16 (Reuters) - Sandoz Group AG SDZ.S:
SANDOZ ANNOUNCES STRATEGIC COLLABORATION WITH HENLIUS ON UP TO 10 BIOSIMILARS, FURTHER EXPANDING INDUSTRY-LEADING PIPELINE
SANDOZ GROUP AG - AGREEMENT FOR UP TO 10 BIOSIMILAR ASSETS REPRESENTS ONE OF LARGEST EVER BIOSIMILAR COLLABORATIONS FOR SANDOZ
SANDOZ GROUP AG - COLLABORATION AGREEMENT WITH SHANGHAI HENLIUS BIOTECH, INC.
SANDOZ GROUP AG - COLLABORATION AGREEMENT IS MILESTONES-BASED FOR A TOTAL CONSIDERATION OF UP TO USD 322 MILLION
SANDOZ GROUP AG - TO HAVE GLOBAL COMMERCIALISATION RIGHTS OUTSIDE CHINA; HENLIUS TO DEVELOP AND MANUFACTURE
SANDOZ ANNOUNCES STRATEGIC COLLABORATION WITH HENLIUS ON UP TO 10 BIOSIMILARS, FURTHER EXPANDING INDUSTRY-LEADING PIPELINE
Source text: ID:nEQ1tlvJNa
Further company coverage: SDZ.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln